GYRE (Gyre Therapeutics) Interest Expense : $0.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Gyre Therapeutics's interest expense for the three months ended in Dec. 2024 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Gyre Therapeutics's Operating Income for the three months ended in Dec. 2024 was $ 0.7 Mil. Gyre Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $ 0.0 Mil. GuruFocus does not calculate Gyre Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gyre Therapeutics Interest Expense Historical Data

The historical data trend for Gyre Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Interest Expense Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Interest Expense

-0.12

-0.04

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial						-	-	-	-	-

Gyre Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Gyre Therapeutics (NAS:GYRE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gyre Therapeutics's Interest Expense for the three months ended in Dec. 2024 was $0.0 Mil. Its Operating Income for the three months ended in Dec. 2024 was $0.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.9 Mil.

Gyre Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Gyre Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Gyre Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.